<SEC-DOCUMENT>0000950123-11-032946.txt : 20110405
<SEC-HEADER>0000950123-11-032946.hdr.sgml : 20110405
<ACCEPTANCE-DATETIME>20110405151330
ACCESSION NUMBER:		0000950123-11-032946
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20110404
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110405
DATE AS OF CHANGE:		20110405

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHAMPIONS ONCOLOGY, INC.
		CENTRAL INDEX KEY:			0000771856
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				521401755
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17263
		FILM NUMBER:		11739744

	BUSINESS ADDRESS:	
		STREET 1:		855 N. WOLFE STREET
		STREET 2:		SUITE 619
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21205
		BUSINESS PHONE:		410-369-0365

	MAIL ADDRESS:	
		STREET 1:		855 N. WOLFE STREET
		STREET 2:		SUITE 619
		CITY:			BALTIMORE
		STATE:			MD
		ZIP:			21205

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAMPIONS BIOTECHNOLOGY, INC.
		DATE OF NAME CHANGE:	20070220

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAMPIONS SPORTS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERNATIONAL GROUP INC
		DATE OF NAME CHANGE:	19860319
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c15195e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV
style="width: 7.2in; font-family: 'Times New Roman',Times,serif; margin-left: 0.25in">
<DIV style="font-size: 10pt">
<DIV
style="border-bottom: black 2pt solid; width: 100%; font-size: 1pt">&nbsp;</DIV>
<DIV
style="border-bottom: black 1pt solid; width: 100%; font-size: 1pt">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): April 4, 2011</B>


<P style="font-size: 24pt" align="center"><B>CHAMPIONS ONCOLOGY,
INC.<BR>
</B><FONT style="font-size: 10pt">(Exact name of registrant as
specified in its charter) </FONT>
<TABLE style="text-align: center; font-size: 10pt" border="0" cellspacing="0"
cellpadding="0" width="100%">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>0-17263</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>52-1401755</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="text-align: center; font-size: 10pt" border="0" cellspacing="0"
cellpadding="0" width="100%">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Science and Technology Park
at Johns Hopkins<BR>
855 N. Wolfe Street, Suite 619, Baltimore,
Maryland<BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>21205</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(410) 369-0365</B>
<TABLE style="text-align: center; font-size: 10pt" border="0" cellspacing="0"
cellpadding="0" width="30%">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>CHAMPIONS
BIOTECHNOLOGY, INC.<BR>
</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>



<DIV
style="border-bottom: black 1pt solid; margin-top: 10pt; width: 100%; font-size: 1pt">&nbsp;</DIV>
<DIV
style="border-bottom: black 2pt solid; width: 100%; font-size: 1pt">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="width: 7.2in; font-family: 'Times New Roman',Times,serif; margin-left: 0.25in">

<P style="font-size: 10pt" align="center"><B>INFORMATION TO BE INCLUDED IN THE
REPORT</B>

<P style="font-size: 10pt" align="justify"><B>Item&nbsp;1.01. Entry into a
Material Definitive Agreement.</B>

<P style="text-indent: 4%; font-size: 10pt" align="justify">On April&nbsp;4,
2011, Champions Oncology, Inc., formerly Champions Biotechnology, Inc., (the
&#8220;<B>Company</B>&#8221;) repurchased 2,000,000 shares of the
Company&#8217;s common stock from James M. Martell, a director of the Company,
for a cash purchase price of $0.48 per share, or an aggregate purchase price of
$960,000.

<P style="font-size: 10pt" align="justify"><B>Item&nbsp;8.01. Other Events.</B>

<P style="text-indent: 4%; font-size: 10pt" align="justify">(A)&nbsp;On
April&nbsp;4, 2011, the Company filed its Amended and Restated Certificate of
Incorporation (&#8220;<B>Amended Charter</B>&#8221;) with the Secretary of
State of Delaware pursuant to which the name of the Company has been changed to
&#8220;Champions Oncology, Inc.&#8221; A copy of the Amended Charter is
included in the Information Statement previously filed and distributed by the
Company in accordance with Securities and Exchange Commission
(&#8220;<B>SEC</B>&#8221;) Regulation&nbsp;14C.

<P style="text-indent: 4%; font-size: 10pt" align="justify">(B)&nbsp;On
April&nbsp;5, 2011, the Company issued a press release announcing the closing
of the sale of 12,533,333 shares of common stock in a private placement in
reliance upon the exemption from registration provided by Section&nbsp;4(2) of
the Securities Act of 1933 and Regulation&nbsp;D promulgated thereunder. In
accordance with SEC Rule&nbsp;135c(d), a copy of the press release is filed
herewith as Exhibit&nbsp;99.1.

<P style="font-size: 10pt" align="justify"><B>Item&nbsp;9.01. Financial
Statements and Exhibits.</B>

<P style="font-size: 10pt" align="justify"><I>(d)&nbsp;Exhibits</I>

<P>
<DIV style="text-align: left">The following exhibits are filed
herewith:</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" border="0" cellspacing="0" cellpadding="0"
width="100%">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="8%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="87%">&nbsp;</TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top">
<DIV style="text-indent: 0px; margin-left: 0px">Exhibit&nbsp;No. </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">&nbsp;</TD>
 </TR>
 <TR style="font-size: 1px">
  <TD style="border-top: #000000 1px solid" valign="top">
<DIV style="text-indent: 0px; margin-left: 0px">&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top">
<DIV style="text-indent: 0px; margin-left: 0px">99.1 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Press release dated April&nbsp;5, 2011</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center"><B>SIGNATURES</B>

<P style="text-indent: 4%; font-size: 10pt" align="justify">Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.

<P style="margin-left: 46%; font-size: 10pt" align="justify"><B>CHAMPIONS
ONCOLOGY, INC.</B> <BR>
(Registrant)

<P style="font-size: 10pt" align="justify">Date: April&nbsp;5, 2011

<P style="margin-top: -11pt; margin-left: 46%; font-size: 10pt"
align="justify">By: &nbsp;<U><B>/</B>s/ Joel
Ackerman&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
<BR>
Joel Ackerman <BR>
Chief executive Officer

<P style="font-size: 10pt" align="right">&nbsp;

<P style="font-size: 10pt" align="center">- 2 -

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c15195exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV
style="width: 7.2in; font-family: 'Times New Roman',Times,serif; margin-left: 0.25in">

<P style="font-size: 10pt" align="right"><U><B>Exhibit&nbsp;99.1</B></U>

<P style="font-size: 10pt" align="center"><B>NEWS RELEASE</B>

<P style="font-size: 10pt" align="center"><B>Champions Oncology (formerly
Champions Biotechnology) Completes $9.4 Million Financing</B>

<P style="font-size: 10pt" align="justify"><B>Baltimore, MD </B>April&nbsp;5,
2011 &#8211; Champions Oncology, Inc. (OTC: CSBR) (&#8220;the Company&#8221;,
formerly known as Champions Biotechnology, Inc.) announced today it has
completed the private placement of 12.5&nbsp;million shares of its common stock
at a price of $0.75 per share, resulting in gross proceeds to the company of
$9.4&nbsp;million.

<P style="font-size: 10pt" align="justify">Proceeds from the financing will be
used to invest in:

<P>
<TABLE style="font-size: 10pt" border="0" cellspacing="0" cellpadding="0"
width="100%">

 <TR
style="background: none transparent scroll repeat 0% 0%; color: #000000; font-size: 10pt"
valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"
width="2%">&nbsp;</TD>
  <TD width="3%" nowrap align="left">&#8226;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify">Sales resources dedicated to growing its
Personalized Oncology Solutions (POS)&nbsp;and Translational Oncology Solutions
(TOS)&nbsp;Businesses.</DIV>
</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" border="0" cellspacing="0" cellpadding="0"
width="100%">

 <TR
style="background: none transparent scroll repeat 0% 0%; color: #000000; font-size: 10pt"
valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"
width="2%">&nbsp;</TD>
  <TD width="3%" nowrap align="left">&#8226;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify">Growing the Tumorgraft<SUP
style="font-size: 85%; vertical-align: text-top">TM</SUP> bank to support the
current TOS business and to further the Company&#8217;s information
assets.</DIV>
</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" border="0" cellspacing="0" cellpadding="0"
width="100%">

 <TR
style="background: none transparent scroll repeat 0% 0%; color: #000000; font-size: 10pt"
valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"
width="2%">&nbsp;</TD>
  <TD width="3%" nowrap align="left">&#8226;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify">Lowering the cost and time required to
generate results from the Tumorgraft<SUP
style="font-size: 85%; vertical-align: text-top">TM</SUP> Technology
Platform.</DIV>
</TD>
 </TR>

</TABLE>


<P>
<TABLE style="font-size: 10pt" border="0" cellspacing="0" cellpadding="0"
width="100%">

 <TR
style="background: none transparent scroll repeat 0% 0%; color: #000000; font-size: 10pt"
valign="top">
  <TD style="background: none transparent scroll repeat 0% 0%"
width="2%">&nbsp;</TD>
  <TD width="3%" nowrap align="left">&#8226;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD>
<DIV style="text-align: justify">And general corporate purposes.</DIV>
</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="justify">Up to $1.4&nbsp;million of the
proceeds will be used to repurchase shares from certain shareholders in one or
more privately negotiated transactions at a discount to $0.75 per share. The
Company has utilized $960,000 of this $1.4&nbsp;million allocation of the
proceeds to complete the repurchase of two million shares from a majority
shareholder at a price of $0.48 per share.

<P style="font-size: 10pt" align="justify">Concurrent with the closing of the
investment, the Company will issue 1,010,000 warrants to certain investors
which will entitle the holders to purchase additional common shares at $0.90
per share for a period of five years, following the date of issuance. In
addition, purchasers of the shares will have the right to require the Company
to repurchase the purchased shares (the &#8220;Put Option&#8221;) for cash for
$0.75 upon a change of control or sale of substantially all of the
company&#8217;s assets. The Put Option will terminate upon the achievement of
certain milestones.

<P style="font-size: 10pt" align="justify">The offer and sale of the shares
have not been registered under the Securities Act of 1933, as amended, and the
shares may not be offered or sold in the United States absent registration
under such act and applicable state securities laws or an applicable exemption
from those registration requirements. The Company has agreed to file a
registration statement covering the resale of the common stock issued in the
private placement. This press release shall not constitute an offer to sell or
the solicitation of an offer to buy nor shall there be any sale of these
securities in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to the registration or qualification under the securities
laws of any such jurisdiction.

<P style="font-size: 10pt" align="justify"><I>This press release contains
&#8220;forward-looking statements&#8221; (within the meaning of the Private
Securities Litigation Act of 1995) that inherently involve risk and
uncertainties. Champions Oncology generally uses words such as
&#8220;believe,&#8221; &#8220;may,&#8221; &#8220;could,&#8221;
&#8220;will,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221;
&#8220;anticipate,&#8221; &#8220;plan,&#8221; and similar expressions to
identify forward-looking statements. One should not place undue reliance on
these forward-looking statements. The Company&#8217;s actual results could
differ materially from those anticipated in the forward-looking statements for
many unforeseen factors. See the Company&#8217;s </I><I>Form 10-K</I><I> for
the fiscal year ended April&nbsp;30, 2010 for a discussion of such risks,
uncertainties and other factors. Although the Company believes the expectations
reflected in the forward-looking statements are reasonable, they relate only to
events as of the date on which the statements are made, and Champions
Oncology&#8217;s future results, levels of activity, performance or
achievements may not meet these expectations. The Company does not intend to
update any of the forward-looking statements after the date of this press
release to conform these statements to actual results or to changes in the
Company&#8217;s expectations, except as required by law.</I>

<P style="font-size: 10pt" align="justify"><B>CHAMPIONS Oncology, Inc.</B>
<BR>
855 N. Wolfe Street, Suite&nbsp;619 <BR>
Baltimore, Maryland 21205 USA.
<BR>
Tel. 410-369-0365

<P style="font-size: 10pt" align="justify"><B>WEB SITE:
</B><U><B>www.championsoncology.com</B></U>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">3
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
